Keros Therapeutics — Third Quarter 2026 Earnings Summary

Keros Therapeutics reported a net income of $14.2 million for the third quarter of 2026, a significant turnaround from the $7.3 million net loss recorded in the same period of 2025, driven primarily by revenue from a license agreement with Takeda. The company advanced its pipeline by dosing the first patient in a Phase 2 clinical trial for rinvatercept in Duchenne muscular dystrophy and nominated the nonclinical asset KER-206 for further investigation into bone remodeling. As of September 30, 2026, the company held $259.5 million in cash and cash equivalents, which is projected to fund operations and capital expenditures into the second half of 2028.